Julia Korell, Ph.D.

Principal Scientist II

Julia Korell brings over a decade of expertise in pharmacometrics, most recently serving as Executive Director and US Head of Pharmacometrics at Boehringer Ingelheim. In her 8 years there, she led efforts in model-informed drug development, contributing to key regulatory submissions and advancing pharmacometric practices.

Her diverse experience spans academia, consulting, and the pharmaceutical industry, where she is recognized for her leadership in quantitative decision-making and data-driven approaches to enhance clinical drug development. Julia holds a PhD in Pharmacometrics from the University of Otago and has completed a Certificate of Achievement in Immunology from Harvard Medical School’s HMX Pro program.

Recent publications by this scientist

Semi-mechanistic population pharmacokinetic modeling of DZIF-10c, a neutralizing antibody against SARS-Cov-2: predicting systemic and lung exposure following inhaled and intravenous administration

January 2, 2025

DZIF-10c (BI 767551) is a SARS-CoV-2-neutralizing recombinant monoclonal antibody designed for both systemic and respiratory tract exposure via intravenous infusion and inhalation. A semi-mechanistic population pharmacokinetic model integrated preclinical and clinical data using allometric scaling to characterize lung and systemic exposure profiles. Simulations showed that inhalation offers effective lung exposure at lower doses, while combining inhalation with intravenous therapy achieves sustained levels in both lungs and systemic circulation, optimizing treatment outcomes.

Read Article